Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) EBITDA (2016 - 2025)

China Pharma Holdings' EBITDA history spans 16 years, with the latest figure at -$1.0 million for Q4 2025.

  • For Q4 2025, EBITDA rose 26.84% year-over-year to -$1.0 million; the TTM value through Dec 2025 reached -$2.9 million, up 39.93%, while the annual FY2025 figure was -$2.9 million, 39.93% up from the prior year.
  • EBITDA reached -$1.0 million in Q4 2025 per CPHI's latest filing, down from -$594147.0 in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$270654.0 in Q1 2023 to a low of -$1.5 million in Q2 2022.
  • Average EBITDA over 5 years is -$956892.8, with a median of -$977654.0 recorded in 2022.
  • Peak YoY movement for EBITDA: tumbled 3502.33% in 2021, then surged 72.32% in 2023.
  • A 5-year view of EBITDA shows it stood at -$836967.0 in 2021, then fell by 29.12% to -$1.1 million in 2022, then dropped by 2.37% to -$1.1 million in 2023, then decreased by 29.03% to -$1.4 million in 2024, then increased by 26.84% to -$1.0 million in 2025.
  • Per Business Quant, the three most recent readings for CPHI's EBITDA are -$1.0 million (Q4 2025), -$594147.0 (Q3 2025), and -$508104.0 (Q2 2025).